Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient

Fuminori Teraishi, Kazuhide Ozaki, Yuichi Shibuya, Yasuo Shima, Toshio Nakamura, Madoka Hamada, Yasuo Fukui, Yutaka Nishioka, Tadashi Horimi, Yoshihiro Uchida

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 83-year-old man was admitted to our hospital for the treatment of advanced ascending colon cancer with liver metastases. He had initially undergone an ileocecal resection for ascending colon cancer. Subsequently, we started oral administration of UFT/LV (UFT 400 mg/day, LV 75 mg/day, and 4 weeks of therapy followed by a week suspension of treatment). After 3 courses, his tumors responded well to treatment, and CT showed marked regression of liver metastases. After 10 courses, liver metastases had almost disappeared. Two years passed without any adverse events since UFT/LV therapy was started. These findings suggest that UFT/LV therapy is very safe and effective for elderly patients with unresectable colorectal cancer.

Original languageEnglish
Pages (from-to)473-475
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number3
Publication statusPublished - Mar 2012
Externally publishedYes

Keywords

  • Colorectal cancer
  • Liver metastases
  • UFT/Leucovorin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient'. Together they form a unique fingerprint.

  • Cite this

    Teraishi, F., Ozaki, K., Shibuya, Y., Shima, Y., Nakamura, T., Hamada, M., Fukui, Y., Nishioka, Y., Horimi, T., & Uchida, Y. (2012). Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient. Japanese Journal of Cancer and Chemotherapy, 39(3), 473-475.